Drug intelligence / Profile preview

MOS105

Development stage: Preclinical
Lead developer: Mosaic Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

MOS105 is a small molecule MDM2 inhibitor developed by Mosaic Therapeutics for the treatment of p53 wild-type (WT) hematological malignancies, including Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). The drug functions by disrupting the interaction between the E3 ubiquitin ligase MDM2 and the tumor suppressor protein p53. In p53 WT cancers, MDM2 is often overexpressed, leading to the constitutive degradation of p53; MOS105 stabilizes p53, allowing it to activate downstream pathways involved in cell cycle arrest and apoptosis. Currently in IND-enabling studies, MOS105 is being positioned for use in combination therapy regimens.

Other names: MOS105MOS-105MOS 105

Targets

MDM2 (Mouse double minute 2 homolog)

Beyond the preview

Go deeper on MOS105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOS105.

Explore the full profile